Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Saroglitazar Magnesium in Primary Biliary Cholangitis
NCT06427395Phase 3Active, not recruiting
- Sponsor
- Zydus Therapeutics
- Start
- Jul 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of saroglitazar magnesium in primary biliary cholangitis (PBC), sponsored by Zydus Therapeutics. Primary endpoint: Treatment-related adverse events at 24 months. Started Jul 2024; status: active, not recruiting.
02
Drugs
saroglitazar magnesium
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT06427395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06427395.